EFG Asset Management North America Corp. Has $3.82 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

EFG Asset Management North America Corp. reduced its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 8.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 322,734 shares of the company’s stock after selling 31,595 shares during the quarter. EFG Asset Management North America Corp.’s holdings in Roivant Sciences were worth $3,820,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. GAMMA Investing LLC boosted its stake in Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after purchasing an additional 1,288 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Roivant Sciences by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock valued at $84,000 after purchasing an additional 1,507 shares in the last quarter. Quarry LP boosted its position in shares of Roivant Sciences by 50.0% during the third quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after buying an additional 2,500 shares during the last quarter. Blue Trust Inc. grew its holdings in Roivant Sciences by 550.1% during the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock worth $91,000 after buying an additional 6,667 shares in the last quarter. Finally, HighTower Advisors LLC purchased a new stake in Roivant Sciences in the 4th quarter valued at $121,000. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Stock Performance

ROIV opened at $10.83 on Tuesday. The firm has a market cap of $7.73 billion, a P/E ratio of -72.20 and a beta of 1.26. Roivant Sciences Ltd. has a fifty-two week low of $9.93 and a fifty-two week high of $13.06. The firm has a 50-day moving average of $10.79 and a 200 day moving average of $11.45.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Equities research analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Roivant Sciences

In related news, CIO Mayukh Sukhatme sold 689,495 shares of the business’s stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $12.01, for a total value of $8,280,834.95. Following the sale, the executive now directly owns 18,836,547 shares in the company, valued at approximately $226,226,929.47. The trade was a 3.53 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Eric Venker sold 177,704 shares of the company’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $11.54, for a total transaction of $2,050,704.16. Following the sale, the chief operating officer now directly owns 740,976 shares in the company, valued at approximately $8,550,863.04. This trade represents a 19.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 2,439,640 shares of company stock worth $27,451,035 over the last ninety days. 7.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have recently issued reports on ROIV shares. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Roivant Sciences has a consensus rating of “Buy” and a consensus price target of $18.08.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.